Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alcon Withdraws EU Application For Retaane

This article was originally published in The Pink Sheet Daily

Executive Summary

The macular degeneration therapy remains "approvable" in the U.S.

You may also be interested in...



Alcon's Retaane Is Again "Approvable" For Wet AMD; Firm May Pursue Risk Reduction Indication Instead

FDA approval would require another trial, but "given the market and given what we know about the compound, we are not planning on initiating an additional study," firm tells "The Pink Sheet" DAILY.

Alcon's Retaane Is Again "Approvable" For Wet AMD; Firm May Pursue Risk Reduction Indication Instead

FDA approval would require another trial, but "given the market and given what we know about the compound, we are not planning on initiating an additional study," firm tells "The Pink Sheet" DAILY.

Alcon's Retaane "Approvable" For Wet Age-Related Macular Degeneration

The firm plans to meet with FDA "to determine the steps necessary to gain final approval." Alcon says it will discuss ongoing studies with anecortave acetate. The ophthalmic agent passed manufacturing inspections, the firm reports.

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel